Supercharging our immune system could tackle cancer

Researchers find new way to “reenergise” immune cells

SUPERCHARGING immune cells could provide an effective way to tackle cancer, according to new research by scientists in Scotland.

The team at the Cancer Research UK Scotland Institute in Glasgow studied how the immune system works and why it becomes “exhausted” by cancer.

T cells, which are the immune system’s front line against disease, eventually become overcome by cancer allowing it to grow.

Their research, published in Cell Reports, has identified a potential way to “boost” T cells, a key defence against cancer.

Lead researcher Professor Victoria Cowling, of the Cancer Research UK Scotland Institute and University of Glasgow, said: “T cells need to rapidly multiply and produce proteins to fight off infections. That requires a huge amount of energy.

“We’ve discovered that a little-known enzyme, called CMTR1, helps switch on the energy supply by changing how certain genes work.

“If we can find ways to boost this process, we could improve how the immune system responds to cancer which could be a game-changer in how we treat the disease.”

CMTR1 plays a vital role in energising T cells, acting as a switch to help the immune cells ramp up their energy production.

The team found that CMTR1 tweaks the instructions inside cells — known as RNA — so that the right versions of energy-related proteins are made.

These proteins help shape the mitochondria, which are like tiny batteries inside cells. With the right shape, mitochondria can produce more energy, helping T cells stay strong and active.

Without CMTR1, the mitochondria break apart and don’t work properly, leaving T cells weak and unable to fight off infections effectively. With CMTR1 present, T cells have more energy allowing them to proliferate and fight infection.

Next steps would be to identify new or existing treatments which increase CMTR1 to give exhausted T cells the power to tackle cancer cells.

Cancer Research UK Director of Research, Dr Catherine Elliott, said: “Scientific breakthroughs like this have the potential to transform how we see and, crucially, how we treat cancer.

“Our immune system is a key area of cancer research and scrutinising how it works can help create real-world impact for those affected by cancer.”

In Scotland, around 34,800* people are diagnosed with cancer each year, with around 16,400** people dying from the disease annually, so finding new ways to tackle the disease is vital.

The study was funded by Cancer Research UK, the European Research Council, the Medical Research Council, and the Wellcome Trust.

NHS Lothian helps pioneer new treatment for kidney cancer patients

A kidney cancer drug has been accepted for use within NHS Scotland and across the UK thanks to an international study, with NHS Lothian and Edinburgh University leading the UK part of the trial.

The treatment, pembrolizumab, is an antibody delivered intravenously as an immunotherapy to reduce the chances of a relapse after kidney cancer surgery.

Thanks to the research, the Scottish Medicines Consortium (SMC) has advised that the drug will now be made available to treat eligible adults with renal cell carcinoma (RCC).

In Scotland, about 1000 patients are diagnosed with RCC each year, and the incidence of the disease has been increasing over time.

Surgery carries the hope of cure if disease is caught early, but about a quarter to half of patients who undergo a nephrectomy (whole or partial kidney removal) have disease recurrence at different sites within three to five years of this.

RCC is generally resistant to chemotherapy and radiation therapy so, until now, there have been no additional treatments that reduce this risk of relapse.

The study showed that, for patients with a raised risk of relapse, pembrolizumab reduced the risk of kidney cancer coming back by a about a third and there are early indications that this is leading to patients living longer.

This has led to the SMC recommending the drug for NHS use and the first non-trial patients are now receiving this new treatment in Edinburgh.

Dr Stefan Symeonides, Senior Lecturer at the University of Edinburgh and Oncology Consultant at the Edinburgh Cancer Centre, said: “Research continues to explore which people might benefit most from this treatment, as pembrolizumab is not always effective or suitable for every patient.

“However, this represents a significant breakthrough in the treatment of kidney cancer as confirmed by UK approvals from the SMC in Scotland and NICE in England and Wales, as well as its incorporation in treatment guidelines from the European Society for Medical Oncology (ESMO).

“Approval of pembrolizumab is welcome news to many RCC patients, who otherwise had no treatment options available to them to prevent or reduce the risk of relapse of the cancer following nephrectomy.”

Visit the University of Edinburgh‘s website to read more.